25.4 C
New York
Saturday, June 13, 2026

Tag: US52635N1037

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsUS52635N1037